BCIQ Profiles

Company Profile Report
0714 adu Duke-Margolis
BioCentury & Getty Images

Politics, Policy & Law

Why FDA is meeting with payers about Aduhelm, other Alzheimer’s mAbs

Duke-Margolis discussion draft stresses the role of stakeholder collaboration to develop evidence about efficacy, safety of AD mAbs

Duke-Margolis discussion draft stresses the role of stakeholder collaboration to develop evidence about efficacy, safety of AD mAbs.

Jul 14, 2021 | 11:49 PM GMT

Answering critical scientific and medical questions about Aduhelm and other potential Alzheimer’s treatments will require cooperation among payers, FDA, drug companies and physicians, according to a discussion guide the Duke-Margolis Center for Health Policy distributed to participants ahead of a private roundtable meeting Wednesday.

The meeting, and a future public meeting on the

Read the full 1137 word article

How to gain access

Continue reading with a
two-week free trial.